A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study)

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 523-525

  De Boer, Marrit K ^a   Wiersma, Durk ^a   Bous, Johan ^a   Sytema, Sjoerd ^a   Van Der Moolen, Andrea E G M ^a   Wilffert, Bob ^b   Hamamura, Takashi ^c   Knegtering, Henderikus ^d,e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Hamamura Clinic   (Japan)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e Lentis Foundation for Mental Healthcare Groningen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OXAZEPAM; PROLACTIN; RISPERIDONE;

ADULT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPERSEXUALITY; LETTER; MALE; NETHERLANDS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSEXUAL DISORDER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SCHIZOPHRENIA; SEXUALITY;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 79960577349     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318222bb29     Document Type: Letter

References (20)

1. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry. 1995;56:137-141.
2. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1995;35:S75-S86. (Pubitemid 29133028)
3. Knegtering H, van den Bosch RJ, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33:711-717.
4. Smith S. Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. J Clin Psychopharmacol. 2003;23(3 suppl 1): S27-S32. (Pubitemid 36807785)
5. Meston CM, Frohlich PF. The neurobiology of sexual functioning. Arch Gen Psychiatry. 2000;57:1012-1030.
6. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154:1-63.
7. Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin. 2004;20:189-197. (Pubitemid 38197320)
8. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404-1410. (Pubitemid 47461141)
9. Knegtering H, Boks M, Blijd C, et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 2006;32:315-326. (Pubitemid 43995227)
10. Knegtering H, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactine levels. Am J Psychiatry. 2005;162:1010-1012. (Pubitemid 40676220)
11. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatement of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465. (Pubitemid 27147597)
12. Knegtering H, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 2004;24:56-61. (Pubitemid 38139316)
13. Taylor D. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract. 2003;57:49-54. (Pubitemid 36181749)
14. Meller E, Puza T, Miller JC, et al. Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro. J Pharmacol Exp Ther. 1991;257:668-675.
15. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314. (Pubitemid 39388605)
16. Knegtering H, Castelein S, Teske A, et al. The development of the antipsychotic and Sexual functioning questionnaire (ASFQ). In: Knegtering H. Antipsychotic Treatment and Sexual Functioning, Role of Prolactin. Groningen, The Netherlands: University Medical Center Groningen; 2003. Available at: http://irs.ub.rug.nl/ppn/254939104. Accessed June 1, 2011.
17. Kearns AE, Goff DC, Hayden DL, et al. Risperidone-associated hyperprolactinemia. Endocr Pract. 2000;6:425-429.
18. Teusch L, Scherbaum N, Bohme H, et al. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts. Pharmacopsychiatry. 1995;28:84-92.
19. Kodama M, Hamamura T. Aripiprazole-induced behavioural disturbance related to impulse control in clinical setting. Int J Neuropsychopharmacol. 2010;13:549-551.
20. Schlachetzki JC, Langosch JM. Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? J Clin Psychopharmacol. 2008; 28:567-568.